Evidence map›Paper›PMID 42228342›Full record

ArticleJapanese journal of radiology2026

Correlation of tumor maximum standardized uptake value from

Yuki Yoshino, Satoshi Takeno, Teruhito Aihara, Kayako Isohashi, Naonori Hu, Yasukazu Kanai, Akinori Sasaki, Mai Nojiri, Tetsuya Terada, Shinichi Haginomori and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Japanese journal of radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Moving beyond SUVJapanese journal of radiology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yuki YoshinoKansai BNCT Medical Center, Educational Foundation of Osaka Medical and Pharmaceutical University, 2-7 Daigakucho, Takatsuki, Osaka, 569-8686, Japan. yuki.yoshino@ompu.ac.jp.ORCID http://orcid.org/0000-0003-0029-3467
Satoshi TakenoKansai BNCT Medical Center, Educational Foundation of Osaka Medical and Pharmaceutical University, 2-7 Daigakucho, Takatsuki, Osaka, 569-8686, Japan.
Teruhito AiharaKansai BNCT Medical Center, Educational Foundation of Osaka Medical and Pharmaceutical University, 2-7 Daigakucho, Takatsuki, Osaka, 569-8686, Japan.
Kayako IsohashiDepartment of Radiology, Graduate School of Medicine, The University of Osaka, Osaka, Japan.
Naonori HuKansai BNCT Medical Center, Educational Foundation of Osaka Medical and Pharmaceutical University, 2-7 Daigakucho, Takatsuki, Osaka, 569-8686, Japan.
Yasukazu KanaiKansai BNCT Medical Center, Educational Foundation of Osaka Medical and Pharmaceutical University, 2-7 Daigakucho, Takatsuki, Osaka, 569-8686, Japan.
Akinori SasakiKansai BNCT Medical Center, Educational Foundation of Osaka Medical and Pharmaceutical University, 2-7 Daigakucho, Takatsuki, Osaka, 569-8686, Japan.
Mai NojiriKansai BNCT Medical Center, Educational Foundation of Osaka Medical and Pharmaceutical University, 2-7 Daigakucho, Takatsuki, Osaka, 569-8686, Japan.
Tetsuya TeradaDepartment of Otorhinolaryngology - Head and Neck Surgery, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Shinichi HaginomoriDepartment of Otorhinolaryngology - Head and Neck Surgery, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Keiji NiheiKansai BNCT Medical Center, Educational Foundation of Osaka Medical and Pharmaceutical University, 2-7 Daigakucho, Takatsuki, Osaka, 569-8686, Japan.
Koji OnoKansai BNCT Medical Center, Educational Foundation of Osaka Medical and Pharmaceutical University, 2-7 Daigakucho, Takatsuki, Osaka, 569-8686, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeBoron neutron capture therapy (BNCT) dose planning conventionally uses a tumor-to-blood (T/B) ratio derived from the tumor maximum standardized uptake value (SUVmax) of fluorine-18-labeled 4-borono-L-phenylalanine ( MATERIALS AND

methodsWe retrospectively analyzed 30 patients with HNC treated with accelerator-based BNCT (2020-2021). The Kaplan-Meier method was used for survival analysis. Dose parameters (Dmax, Dmin, and D80%) were calculated using the uniform model (T/B = 2.5) and the individual model (T/B = Tumor SUVmax/Blood-pool SUV). Correlations between tumor SUVmax or dose parameters and best treatment response [complete response (CR) vs. non-CR] were evaluated using the Mann-Whitney U test.

resultsThe objective response rate was 90%, and the CR rate was 50%. CR status strongly predicted superior 2 years overall survival, locoregional control, and progression-free survival (all p < 0.05). However, no significant differences were observed between the CR and non-CR groups for tumor SUVmax, uniform model doses, or individual model doses (all p > 0.05).

conclusion

Indexed as

Boron CompoundsBoron Neutron Capture TherapyHead and Neck NeoplasmsPhenylalaninePositron-Emission TomographyAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedRadiopharmaceuticalsRadiotherapy DosageRetrospective StudiesTreatment Outcome4-borono-2-fluorophenylalanineBoron CompoundsPhenylalanineRadiopharmaceuticals18F-BPA PET/CTBNCTHead and neck cancerTreatment response

Identifiers

PMID42228342
PMCPMC13623982

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.